SCHEMBL2969915

SCHEMBL2969915

COc1ccc(-c2ccc(=O)n(Cc3ccccc3)n2)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 5/20 0.67
PDE4A P27815 4/20 0.67
PDE4C Q08493 4/20 0.67
PDE4D Q08499 4/20 0.67
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PIK3CA P42336 1/20 0.51
MTOR P42345 1/20 0.51
CHEK1 O14757 1/20 0.50
NEK2 P51955 1/20 0.50
LIMK1 P53667 1/20 0.50
TYRO3 Q06418 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
PDE5A O76074 1/20 0.49
PDE3A Q14432 1/20 0.49
KDR P35968 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26627234 0.89 PDE4A (0.53) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL23297341 0.89 PDE4A (0.53) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL26999003 0.84 PDE4B (0.54) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL23297368 0.83 PDE4B (0.71) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL4122168 0.81 KDR (0.54) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL11140135 0.79 POLB (0.74) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL5440197 0.79 KDR (0.56) PIK3CAMTORHRH3KDR
SCHEMBL3841611 0.78 MAPT (0.70) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL24029943 0.78 MKNK1 (0.49) PDE4BPDE4APDE4CPDE4DPOLB
SCHEMBL15815000 0.77 PDE4B (0.80) PDE4BPDE4APDE4CPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763617-B2 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-7763617-B2 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-7763617-B2 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient PDE5A, PDE3A, PDE3B PDE4B 7/4885PDE4A 5/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.